# randOmized stUdy Using acceleromeTry to Compare Sacubitril/valsarTan and Enalapril in Patients With Heart Failure

Study · id `cardio:ct-nct02900378` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT02900378](<https://clinicaltrials.gov/study/NCT02900378>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT02900378

Browse, organ or system: Heart  
Browse, condition area: Heart failure  

## In plain language

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 621 participants.

## Technical summary

Registry record NCT02900378. Randomized; triple masking; primary purpose treatment. Start 2016-12-20 (actual); primary completion 2018-04-11 (actual). Results posted on 2019-09-16.

## Key facts

- Design: Interventional study; randomized; triple masking; primary purpose treatment
- Phase: Phase 3
- Enrolled: 621 participants (enrolled count; ClinicalTrials.gov record NCT02900378, source copy `cardio:ctgov-nct02900378-2020-09-02`, retrieved 2026-10-26)
- Started: 2016-12-20 (actual) (ClinicalTrials.gov record NCT02900378, source copy `cardio:ctgov-nct02900378-2020-09-02`, retrieved 2026-10-26)
- Primary completion: 2018-04-11 (actual) (ClinicalTrials.gov record NCT02900378, source copy `cardio:ctgov-nct02900378-2020-09-02`, retrieved 2026-10-26)
- Completion: 2018-04-11 (actual) (ClinicalTrials.gov record NCT02900378, source copy `cardio:ctgov-nct02900378-2020-09-02`, retrieved 2026-10-26)
- Results first posted: 2019-09-16 (ClinicalTrials.gov record NCT02900378, source copy `cardio:ctgov-nct02900378-2020-09-02`, retrieved 2026-10-26)
- Countries: Belgium; Bulgaria; Czechia; Denmark; Estonia; Finland; France; Germany; Greece; Iceland; Ireland; Latvia; Lithuania; Netherlands; Norway; Poland; Spain; Sweden; United Kingdom (ClinicalTrials.gov record NCT02900378, source copy `cardio:ctgov-nct02900378-2020-09-02`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct02900378-2020-09-02`, retrieved 2026-10-26)

## The registry's words

- Brief title: randOmized stUdy Using acceleromeTry to Compare Sacubitril/valsarTan and Enalapril in Patients With Heart Failure
- Acronym: OUTSTEP-HF
- Condition: Chronic Heart Failure With Reduced Ejection Fraction
- Intervention (Drug): LCZ696 (Sacubitril/Valsartan)
- Intervention (Drug): Placebo of LCZ696 (Sacubitril/Valsartan)
- Intervention (Drug): Enalapril
- Intervention (Drug): Placebo of Enalapril
- Lead sponsor: Novartis Pharmaceuticals
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Heart failure (`cardio:heart-failure`)
- Registry intervention name matches this record: Enalapril (`cardio:enalapril`)
- Registry lists this organization as the lead sponsor: Novartis (`cardio:novartis`)

## Provenance

Content hash: 7a5a7fca700541abdaca7fb5002f0cdc0011f16e81938565a01e567a8feaa455
Last substantive edit: 2026-11-18
Evidence last checked: Not recorded
